Selected Conference Presentations

63rd Annual American Society of Hematology (ASH) Meeting and Exposition: December 11 – 14, 2021 

* Indicates ASH Abstract Achievement Award

1. Pharmacogenomics of Fludarabine in Pediatric HCT Recipients: Preliminary Results *
2. Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant
3. The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed Gemtuzumab Ozogamicin
4. Pharmacogenomics to Predict Mucositis in Acute Myeloid Leukemia
5. Pharmacogenomic Single Nucleotide Polymorphism (SNP) Variants As Predictors of Toxicity Phenotypes in the Treatment of Acute Childhood Leukemia
6. Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML *
7. A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML *

American Society for Clinical Pharmacology & Therapeutics Annual Meeting: March 16 – 18, 2022

*Indicates Presidential Trainee Award; **Presidential Trainee Award and David J. Goldstein Trainee Award

1. Pharmacogenomic Single Nucleotide Polymorphism (SNP) Scores as a Tool to Predict Toxicity Phenotypes in Treatment of Acute Childhood Leukemia (ALL) **
2. A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGX) Score Predicts Response to Gemtuzumab Ozogamicin in Pediatric AML Patients *

American Association for Cancer Research (AACR) Annual Meeting: April 9 – 14, 2021

1. Leukemic cell proteomic profiling in pediatric AML – Abstract No. 2535